Natural and therapeutically-induced antibodies to cytokines

Biotherapy

Volumn 10, Issue 4, 1998, Pages 321-331

  Revoltella, Roberto P ^a  

^a CNR   (Italy)

Author keywords

Auto immunity; Auto antibodies; Cytokines; Hematopoiesis; Natural regulators; Neonatal immunity; Receptors

Indexed keywords

AUTOANTIBODY; CYTOKINE; ERYTHROPOIETIN; GROWTH HORMONE; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; INTERFERON; PLATELET DERIVED GROWTH FACTOR RECEPTOR; TUMOR NECROSIS FACTOR;

ANTIBODY AFFINITY; ARTICLE; AUTOIMMUNITY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOBLOTTING; IMMUNOGENICITY; IMMUNOSTIMULATION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SIGNAL TRANSDUCTION; VIRUS GENE;

EID: 0031920770     PISSN: 0921299X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02678552     Document Type: Article

References (108)

1. Metcalf D. The hemopoietic colony stimulating factors. Amsterdam: Eisevier, 1984.
2. Trotta PP. Cytokines: an overview. Am J Reprod Immunol 1991; 25: 137-41.
3. Williams ME, Queensbeny PS. Hematopoietic growth tactors. Hematol Pathol 1992; 6: 105-19.
4. Bernard C, Tedgui A. Cytokine network and the vessel well: Insights into septic shock pathogenesis. Eur Cytokine Net 1992; 3: 19-33.
5. Wong GG, Witek JS, Temple PA, Wilkens KO, Leary AC, Luxemberg DP, Jones SS, Brown EL, Kay RM, Orr EC, Shoemaker C, Golde DW, Kaufman RJ, Hewick RM, Wang EA, Clark SC. Human GM-CSF: Molecular cloning of the complementary DNA and purification of the natural and recombinant proteins. Science 1985; 228: 810-5.
6. Lopez AF, Williamson DJ, Gamble JR, Begley G, Harlam J, Klebanhoff PI, Waltersdorph A, Wong GG, Clark SC, Vadas M. Recombinant human granulocyte-macrophage colonystimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression and survival. J Clin Invest 1986; 78: 1220-2.
7. Dedhar S, Gaboury L, Galloway P, Eaves C. Human granulocyte-macrophage colony stimulating factor is a growth factor, active on a variety of cell types of nonhematopoietic origin. Proc Natl Acad Sci.USA 1988; 85: 9253-7.
8. Bussolino F, Wang JM, Defilippi P, Tunini F, Sanavio F, Edgell OS, Aglietta M, Arese P, Mantovani A. Granulocyteand granulocyte-macrophage colony-stimulating factors induce human endothelial cells to migrate and proliferate. Nature 1989; 337:471-3
9. Baldwin GC. The biology of granulocyte-macrophage colony stimulating factor: Effects on hematopoietic and nonhematopoietic cells. Dev Biol 1992; 151: 352-67.
10. Modrowski D, Lomri A, Mariel PJ. Endogenous GM-CSF is involved as an autocrine growth factor for human osteoblastic cells. J Cell Physiol 1997; 170: 35-46.
11. Steven C, Clark SG, Kamen R. The human hematopoietic colony-stimulating factors. Science 1987; 236: 1229-37.
12. Lopez AF, Eglinton JM, Lyons AB, Tapley PM, To LB, Park LS, Clark SC, Vadas AM. Human interleukin-3 inhibits the binding of granulocyte-macrophage colony stimulating factor and rnterleukin-5 to basophiles and strongly enhances their functional activity, J Cell Physiol 1990; 45: 69-77.
13. Elliott MJ, Vadas MA, Cleland LG, Gamble JR, Lopez AF. 11-3 and granulocyte-macrophage colony stimulating factor stimulate two distinct phases of adhesion in human monocytes. J Immunol 1990; 145: 167-76.
14. Korpelainen El, Gamble JR, Smith WB, Goodall GJ, Qiyu S, Woodcock JM , Dottore M, Vadas MA.Lopez AF. The receptor for interleukin-3 is selectively induced in human endothelial cells by tumor necrosis factor a and potentiates interleukin-8 secretion and neutrophil transmigration. Proc Nad Acad Sei USA 1993; 90: 11137-41.
15. Bendtzen K. Immune hormones (cytokines): pathogenic role in autoimmune rheumatic diseases and endocrine diseases. Autoimmunity 1989; 2: 177-89.
16. Williams JG, Jurkovich GJ, Maier RV. Interferon-y: a key immunoregolatory lymphokine. J Surg Res 1993; 54: 74-93.
17. Kilbourn RG, Belloni P. Endothelial cell production of nitrogen oxides in response to interferons in combination with tumor necrosis factor, interleukinl, or endotoxin. J Nat Cancer Inst 1990; 82: 772-6.
18. Bendtzen K. Interleukinl, interleukino and tumor necrosis factor in infection, inflammation and immunity. Immunol Lett 1988; 19: 183-92.
19. Bendtzen K. Clinical significance of cytokines:natural and therapeutic regulation. Sem Clin Immunol 1991; 3: 5-13.
20. Sartor RB. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology 1994; 106: 533-9.
21. Kovacs EJ. Fibrogenic cytokines: the role of immune mediators in the development of scar tissue. Immunol Today 1991 ; 12: 17-23.
22. Edwards MJ, Heniford BT, Miller FN. Tumor necrosis factor mediates disseminated intramuscular inflammation (DI1) in the genisis of multiple organ edema. J Surg Res 1993; 54: 140-4.
23. Mateo RB, Reichner JS, Albina JE. Interleukin-6 activity in wounds. Am J Physiol Regul Integr Comp Physiol 1994; 266: R1840-4.
24. Nilsson J. Cytokines and smooth muscle cells in atherosclerosis. Cardiovasc Res 1993; 27: 1184-90.
25. Dower SK, Sims JE.Cerretti DP, Bird TA. The interleukinl system: receptors, ligands and signals. Clin Immunol 1992; 51: 33-64.
26. Moore KW, O'Garra A, De Waal Malefyt R, Vieira P, Mossman. InterleukinlO. Ann Rev Immunol 1993; 11: 165-190.
27. Howard M, O'Garra A, Ishida H, De Waal Malefyt R, De Vries J. Biological properties of interleukinlO. J Clin Immunol 1992; 12: 239-47.
28. Trinchieri G, Kubin M, Bellone G, Cassatella MA. Cytokine cross-talk between phagocytic cells and lymphocytes: relevance for differentiation/activation of phagocytic cells and regulation of adoptive immunity. J Cell Biochem 1993; 53: 301-8.
29. Moore KW, Roussel F, Boucherai) J. Evoking principles in immunopathology: interleukinlO and its relationship to Epstein-Barr virus protein BCR1. Springier Sem Immunopathol 1991; 13: 157-66.
30. Arai K, Lee F, Miyajima A, Miyatakes, Arai N, Yokota T.Cytokines: coordinators of immune and inflammatory responses Ann Rev Biochem 1990; 59: 783-836.
31. Bagley CJ, Woodcock JM, Stomski FC, Lopez AF. The structural and functional basis of cytokine receptor activities: Lessons from the common subunit of the granulocytemacrophage colony-stimulating factor, Interleukin 3 (11-3) and n-5 receptors. Blood 1997; 89: 1471-82.
32. Goodall GJ, Bagley CJ, Vadas MA, Lopez AF. A model for the interaction of the GM-CSF, 11-3 and 11-5 receptors with their ligands. Growth Factors 1993; 8: 87-92.
33. Zurawski SM, Vega F, Huyghe B, Zurawski G. Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that function in signal transduction. EMBO J 1993; 12: 2663-8.
34. Mui AL, Miyajima A. Cytokine receptors and signal transduction. Prog Growth Factor Res 1994; 5:15-8.
35. Me JN. Cytokine receptor signalling. Nature 1995; 377: 591-2
36. Me JN, Witthuhn BA, Quelle FW, Yamamoto K, Silvennoinen O. Signalling through the hematopoietic cytokine receptors. Ann Rev Immunol 1995; 13: 369-98.
37. Heaney ML, Golde DW. Soluble hormone receptors. Blood 1993; 82: 1945-8.
38. Heaney ML, Vera JC, Raines MA, Golde DW. Membrane associated and soluble granulocyte-macrophage colonystimulating factor receptor a subunits are independently regulated in HQ.60 cells. Proc Natl Acad Sei USA 1995; 92: 2365-9.
39. Barak V. Soluble cytokine receptors in disease. Israel J Med Sei 1995; 31: 565-71.
40. Lloyd AR, Johnston J. Cytokines and cytokine receptors in health and disease. A summary of the National Heart, Lung and Blood Institute Frontiers in Basic Sciences Symposium. Cytokine 1993; 5: 399 07.
41. Gambier JC. Inhibitory receptors abund? Proc Naü Acad Sei USA 1997; 94: 5993-5.
42. Kubargawa H, Burrows PD, Cooper DA A novel pair of immunoglobulin-like receptors expressed by B-cells and myeloid cells. Proc Natl Acad Sei USA 1997; 94: 5261-6.
43. Fujioka Y, Matozaki T, Noguchi T, Iwamatsu A, Yamao T, Takahashi N, Tsuda M, Takada T, Kasuga M. A novel membrane glycoprotein, SHPS-1, that binds the SH2-domaincontaining protein tyrosine phosphatase SHP-2 in response to nitrogens and cell adhesion. Mol Cell Biol 1996; 16: 6887-99.
44. Kharitonenkov A, Chen ZJ, Sures I, Wang HY, Schilling J, Ullrich A. A family of proteins that inhibit signalling through tyrosine kinase receptors. Nature 1997; 386: 181-6.
45. Klingmüller V, Lorenz V, Cantley LC, Neel BG, Lodish HF. Specific recruitment of SH-PTP1 to the erythropoietin receptor cause inactivation of JACK2 and termination of proliferate signals. Cell 1995; 80: 729-36.
46. D'Ambrosio D, Hippen KL, Minskoff SA, Mellman I, Pani G, Siminovitch KA, Cambier JC. A novel membrane glycoprotein, SHPS-1, that binds the SHP-2 in response to mitogens and cell adhesion. Science 1995; 268: 293-7.
47. Bendtzen K. Cytokines and natural regulators of cytokines. Immunol Lett 1994; 43: 111-23.
48. Bendtzen K, Svenson M, Forsgaard A, Poulsen LK. Immunol Today 1989; 10: 222-5
49. Webster ADB, Efter T, Asheron GL. Escherichia Coli antibody: a screening test for immunodeficiency. Br Med J 1974; 3: 16-24
50. Hansen MB, Ross C, Berg K. A sensitive antiviral neutralization bioassay for measuring antibodies to interférons. J Immunol Meth 1989; 127: 241-6.
51. Caruso A, Foresti I, Gribaudo G, Bonfanti C, Pollara P, Dolei A, Landolfo S, Turano A. Anti-interferon-y antibodies in sera from HIV infected patients. J Biol Reg Homeost Agents 1989; 3: 8-12.
52. Caruso A, Bonfanti C, Colombrita D, De Francesco M, De Rango C, Foresti I, Gargiulo F, Gonzales R, Gribaudo G, Landolfo S, Manca N, Nanni M, Pinali F, Pollara P , Ravizzola G, Scura G, Terlenghi L, Viani E, Turano A. Natural antibodies to IFN-y in man and their increase during viral infection. J Immunol 1990; 144. 685-90
53. Viani E, Flamminio, Caruso A, Foresti I, De Francesco M, Pollara P, Balsari A, Turano A. Purification of natural human IFN-y antibodies. Immunol Lett 1991; 30: 53-8
54. Hansen MB, Svenson M, Bendtzen K. Serum-induced suppression of interferon (IFN) activity. Lack of evidence for the presence of specific autoantibodies to IFNa in normal human sera. Clin Exp Immunol 1992; 88: 559-62
55. Bendtzen K, Hansen MB, Diamant M, Ross C, Svenson M. Naturally occurring autoantibodies directed against interferon-a in pharmaceutically prepared human immunoglobin preparations J Interferon Res 1994; 14.159-60.
56. Turano A, Babari A, Viani E, Landolfo S, Zanoni L, Gargiulo F, Caruso A.Natural human antibodies to y-interferon interfere with the immunomodulating activity of the lymphokine. Proc Natl Acad Sei USA 1992; 89: 4447-51.
57. Itri LM, Campion M, Dennin RA, Palleroni AV, Gutterman JV, Groopman JE, Trown PT. Incidence and clinical significance of neutralizing antibodies in patients receiving interferon alfa-2a by intramuscular injection. Cancerl987; 59: 668-74
58. Priimmer O, Porzsolt F, the DELTA-P Study Group. Recombinant interferon or antibodies in renal cell carcinoma. J Interferon Res 1994; 14: 193-5
59. Caruso A, Folghera S, Martinelli F, Turano A. Natural antibodies to interferon-y in humans: Inhibition of the biological activity of IFN-y by human anti IFN-y antibodies J Interferon Res 1994; 14. 161.
60. Bakhiet M, Mahamustafa AD, Jiezhv JS, Lindqvist L, Link H. Potential role of autoantibodies in the regulation of cytokine responses during bacterial infections. Infection and Immunity 1997; 65: 3300-3
61. Panem S, Check IJ, Henriksen D, Vilcek J. Antibodies to ainterferon in a patient with systemic lupus erythematosus. J Immunol 1982; 129: 1-3
62. Bendtzen K, Svenson M, J0nsson V, Hippe E. Autoantibodies to cytokines- friends or foes? Immunol Today 1990; 11.1679.
63. Svenson M, Poulsen LK, Fomsgaard A, Bendtzen K.IgG autoantibodies against interleukin la in sera of normal individuals. Scand J Immunol 1989; 29: 489-92.
64. Hansen MB, Svenson M, Bendtzen K. Human antiinterleukin la antibodies. Immunol Lett 1991; 30: 130-40.
65. Svenson M, Hansen MB, Kayser L, Rasmussen AK, Reimert CM, Bendtzen K. Effects of human -anti II-la autoantibodies on receptor binding and biological activity of II-1. Cytokine 1992; 4: 125-33.
66. Hansen MB, Svenson M, Diamant M, Bendtzen K. Highaffinity IgG autoantibodies to 11-6 in sera of normal individuals are competitive inhibitors of 11-6 in vitro. Cytokine 1993; 5: 72-80.
67. Suzuki H, Takemura H, Yoshizaki K, Koishihara Y, Ohsugi Y, Okano A, Akiyama Y, Tojo T, Kishimoto T Kashiwagi H. Il-6-anti-Il-6 autoantibody complexes with 11-6 activity in sera from some patients with systemic sclerosis J Immunol 1994; 152: 935-42
68. Finkelman FD, Madden KB, Morris SC, Holmes JM, Boiani N, Katona IM, Maliszewski CR. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine anti-cytokine antibody complexes. J Immunol 1993; 151: 1235-44
69. Suzuki H, Akama T, Okane A, Kono I, Matsui Y, Yamane K, Kashiwagi H.Interleukin la inhibitory IgG in sera from some patients with rheumatoid arthritis. Arthritis Rheum 1989; 32: 1528-30
70. Sanrat JH, Schifferli J, Steiger G, Dayer JM, Didierijean L. Anti-interleukin-la autoantibodies in humans: characterization, isotype distribution, and receptor binding inhibition. Higher frequency in Schnitzler's syndrome (urticaria and macroglobulinemia) J Allergy Clin Immunol 1991; 88: 244-7
71. Fomsgaard A, Svenson M, Bendtzen K. Autoantibodies to tumor necrosic factor a in healthy humans and patients with inflammatory diseases and gram-negative bacterial infections. Scand J Immunol 1989; 30: 219-22.
72. Peichl P, Ceska M, Broell H, Effanberger F, Lindley IJD. Human neutrophil-activating peptide/interleukin-8 acts as an auto-antigen in rheumatoid arthritis. Ann Rhem Dis 1992; 51: 19-21
73. Chen TT, Tao MH, Levy R. Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of 11-2, 11-4 and granulocyte-macrophage colony stimulating factor. J Immunol 1994; 153: 4475-787
74. Chen TT, Levy R. Induction of auto-antibody response to GM-CSFby hypenmmunization with an id- GM-CSF fusion protein J Immunol 1995; 154: 3105-17
75. Rönnblom LE, Alm GV, Öberg KE. Auto-immunity after alpha-interferon therapy for malignant carcinoid tumors. Ann tot Med 1991; 115: 178-83
76. Öberg KE. Autoimmunity and antibodies to interferons in patients with carcinoid tumors. Clinical consequences. J Interferon Res 1992; 14: 215-6
77. Gribben JG, Devereux S, Thomas NSB, Klein M, Jones HM, Goldstone AH, Linch DC. Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF The Lancet 1990; 335: 434-7
78. Mellstedt H. Induction of anti-granulocyte-macrophage colony-stimulating factor antibodies against exogenous nonglycosylated GM-CSF: biological implications. J Interferon Res 1994; 14: 179-80
79. Ragnhammer P, Friesen HJ, Frödin JE, Lefvert AK, Hassan M, Österborg A, Mellstedt H. Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia Co//-derived) antibodies and clinical effects in non immunocompromised patients. Blood 1994; 84: 407887
80. Ragnhammer P, Fayerberg J, Frödin JE, Wersäll P, Hansson LO, Mellstedt H. Granulocyte-macrophage colonystimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies. Cancer Immunol Immunother 1995; 40: 367-75
81. Revoltella RP, Laricchia Robbio L, Liberati AM. Natural and therapy-induced anti-GM-CSF antibodies in human serum. Challenges of Modem Medicine (S.Waxman ed.) 1995; 10: 463-70
82. Revoltella RP, Laricchia Robbio L, Moscato S, Genua A, Liberati AM. Natural and therapy-induced anti-GM-CSF and anti-G-CSF antibodies in human serum. Leuk Lymphoma 1997; 26(51): 29-39
83. Laricchia Robbio L, Moscato S, Genua A, Liberati AM, Revoltella RP. Naturally occurring and therapy-induced antibodies to human granulocyte- colony stimulating factor (G-CSF) in human serum. J Cell Physiol 1997; 173: 219-25
84. Malik STA, Naylor S, East N, Oliff A, Belkwill FR. Cells secreting tumor necrosis factor show enhanced metastasis in nude mice. J Eur Cancer 1990; 26(10): 1031-4
85. Oliff A, Defoe Jones D, Boyer M, Martinez D, Kiefer D, Vuocolo G, Wolfe A, Socher SH. Tumor secreting human TNF/cachectin induce cachexia in mice. Cell 1987; 50 (4): 553-63
86. Teng MN, Park BH, Koepper HK, Tracey KJ, Fendly BM, Schreiber H. Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity. Proc Natl Acad Sei USA 1991; 88: 3535-9.
87. Asher AL, Mule JJ, Kasid A, Restifo NP, Salo JC, Reichert CM, Jaffe G, Fendly B, Kriegler M, Rosenberg SA. Murine tumor cells transduced with the gene for tumor necrosis factor alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors. J Immunol 1991; 146: 3227-34
88. Tahara H, Zeh HJr, Storkus WJ, Pappo I, Watkins SC, Gubler V, Wolf SF, Robbins PD, Lotze MT. Fibroblasts genetically engineered to secrete interleukin-12 can suppress tumor growth and riduce antitumor immunity to a murine melanoma in vivo. Cancer Res 1994; 54: 182-9
89. Pappo I, Tahara H, Robbins PD, Gately MK, Wolf SF, Barnea A, Lotze MT. Administration of systemic or local interleukin-12 gene therapy. J Surg Res 1995; 58: 218-26
90. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sei USA 1993; 90: 353913.
91. Bendtzen K, Hansen MB, Ross C, Poulsen LK, Svenson M. Cytokines and autoantibodies to cytokines. Stem cells 1995; 13. 206-22.
92. Ross C, Svenson M. Hansen MB.Veijbgaard GL, Bendtzen K. Specific autoantibodies directed against lnterferon-a in pharmaceutically prepared human immunoglobulin preparations. J Interferon Res 1994; 14. 159-60.
93. Ross C, Svenson M. Hansen MB.Veijbgaard GL, Bendtzen K. High-affinity IFN-neutralizing antibodies in pharmaceutically prepared human IgG. J Clin Invest 1995; 95. 1974-82
94. Ross C, Svenson M. Nielsen H, Lundsgaard C, Bagge, Hansen MB, Bendtzen K. Increased in vivo antibody activity against interferon-a, interleukin-la and interleukin-6 after high-dose therapy. Blood 1997; 90: 2376-80
95. Consensus statement: Intravenous immunoglobulin: Prevention and treatment of disease (vol. 8) NIH Consensus Development Conference Bethesda MD, May 21-23, 1990
96. Dwyer JM. Manipulating the immune system with immune globulins. N Engl J Med 1992; 326, 107-12.
97. Thornton CA, Griffs RC. Plasma exchange and intravenous immunoglobulin treatment of neuromuscular disease. Ann Neural 1994; 35: 260-4
98. Svenson M. Hansen MB, Bendtzen K. Binding of cytokines to pharmaceutically prepared human immunoglobulin. J Clin Invest 1993; 92: 2533-9.
99. Bendtzen K, Svenson M, Hansen MB. Autoantibodies to cytokines in IVIG. J Rheumatol 1993; 20: 2176-7
100. Vakil M, Kearney JF. Regulatory influences of neonatal multispecific antibodies on the developing B-cell repertoire. Inter Immunol 1988; 3: 117-31
101. Kearney JF, Berthels J, Hamilton AM, Lehuen A, Solvason N, Vakil M. Development and function of the early B-cell repertoire.Int Rev Immunol 1992; 8: 247-75
102. Kearney JF. CDS B-cell networks in development. Curr Opin Immunol 1993; 2: 223-6
103. Kearney JF. Formation of autoantibodies, including anticytokine antibodies, is a hallmark of the immune response of early B-cells. J Interferon Res 1994; 14: 151-2
104. Hurez V, Kaveri SV, Kazatchkine MD. Expression and control of IgG autoactivity in normal human serum. EUT J Immunol 1993; 23: 783-9
105. Kazatchkine MD. Natural IgG autoantibodies in the sera of healthy individuals. J Interferon Res 1994; 14. 165-8.
106. Algiman M, Dietrich G, Nydegger VE, Boieldien D, Sulton Y, Kazatchkine MD. Antibodies to factor VIII (antihemophilic factor) in healthy individuals. Proc Nad Acad Sei USA 1992; 89: 3795-9
107. Avrameas S. Natural autoantibodies: From 'Horror autotoxicus' to 'gnothi sauton'. Immunol Today 1991; 12: 154-9
108. Bost K, Hahn BH, Saag MS, Shaw GM, Weigent DA, Blalock JE. Individuals infected with HIV possess antibodies against 11-2. Immunology 1988; 65: 611-5